Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Genitourinary 1Endocrine 1CNS 1

Conditions

Gastro-enteropancreatic neuroendocrine tumor 2Pheochromocytoma 1Paraganglioma 1Oncogenic osteomalacia 1Metastatic Neuroendocrine Prostate Cancer 1Meningioma 1Kidney Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Medullary 1Carcinoid Tumor 1

Interventions

Cisplatin 35pembrolizumab 29Radiotherapy 26Cetuximab 26Docetaxel 17Paclitaxel 13Fluorouracil 13Cyclophosphamide 12fludarabine 11Radiotherapy, Intensity-Modulated 11Nivolumab 10Carboplatin 9atezolizumab 7Radiation 7Gemcitabine 7Erlotinib Hydrochloride 7Bortezomib 7fludarabine phosphate 6Pemetrexed 5Interleukin-2 5Radiosurgery 4Everolimus 4Drug Therapy 4Azacitidine 4olaparib 3motexafin gadolinium 3durvalumab 3cemiplimab 3Trastuzumab 3Irinotecan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Head and Neck Neoplasms × gallium Ga 68 dotatate × Clear all
NCT06479811 2026-04-28

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
120 enrolled
CNSEndocrineGenitourinaryHead & Neck

Head and Neck Neoplasms, Kidney Neoplasms, Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡